United Health Products (OTCMKTS:UEEC – Get Free Report) and MacroGenics (NASDAQ:MGNX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.
Valuation and Earnings
This table compares United Health Products and MacroGenics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| United Health Products | N/A | N/A | -$2.67 million | N/A | N/A |
| MacroGenics | $157.08 million | 1.74 | -$74.62 million | ($1.10) | -3.91 |
Profitability
This table compares United Health Products and MacroGenics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| United Health Products | N/A | N/A | -783.98% |
| MacroGenics | -44.79% | -147.80% | -28.40% |
Insider and Institutional Ownership
0.1% of United Health Products shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 1.5% of United Health Products shares are owned by company insiders. Comparatively, 13.6% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and recommmendations for United Health Products and MacroGenics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| United Health Products | 0 | 0 | 0 | 0 | 0.00 |
| MacroGenics | 1 | 3 | 3 | 0 | 2.29 |
MacroGenics has a consensus price target of $5.50, indicating a potential upside of 27.91%. Given MacroGenics’ stronger consensus rating and higher possible upside, analysts plainly believe MacroGenics is more favorable than United Health Products.
Risk & Volatility
United Health Products has a beta of -0.28, meaning that its share price is 128% less volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.
Summary
MacroGenics beats United Health Products on 8 of the 11 factors compared between the two stocks.
About United Health Products
United Health Products, Inc. develops, manufactures, and markets hemostatic gauze products for the healthcare and wound care sectors in the United States. The company offers HemoStyp hemostatic gauze products to absorb exudate/drainage from superficial wounds, as well as helps in controlling bleeding. It serves hospitals and surgery centers, clinics and physicians, military medical care providers, hemodialysis centers, nursing homes and assisted living, and veterinary hospitals; and EMS, fire departments, and other first responders, as well as dental, oral, and maxillofacial surgery offices. The company was formerly known as United EcoEnergy Corp. and changed its name to United Health Products, Inc. in September 2010. United Health Products, Inc. was incorporated in 1997 and is headquartered in Mount Laurel, New Jersey.
About MacroGenics
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Receive News & Ratings for United Health Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Health Products and related companies with MarketBeat.com's FREE daily email newsletter.
